In biotechnology, humanized monoclonal antibodies are engineered antibodies that primarily originate from non-human species, such as mice, but are modified to reduce their human immunogenicity. The process involves combining specific regions of antibodies from different species to optimize safety and efficacy for human use.
Humanized monoclonal antibodies typically consist of:
Thus, humanized monoclonal antibodies are a combination where the heavy and light chain constant domains are from humans, while the variable domains are from mice. This configuration helps maintain the antibody's specific binding ability while minimizing immune rejection.